SEVER LIFE SCIENCES B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR OCULAR SURFACE CONTROL, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026

DOYLESTOWN, Pa., Oct. 7, 2026 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will feature LACRIFILL® Canalicular Gel, a novel therapy for ocular surface control, during the American Academy of Ophthalmology Annual Meeting in New Orleans, LA, from October...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.